Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Trimebutine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.90 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.90 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.90 |
| ▸ | MTOR known ✓ | P42345 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.90 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.90 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.90 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.90 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimebutine SCHEMBL28274910 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| Trimebutine SCHEMBL1652810 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| Trimebutine SCHEMBL5011979 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| Trimebutine SCHEMBL25705 | 0.95 | OPRM1 (1.00) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| Trimebutine SCHEMBL14273976 | 0.95 | OPRM1 (1.00) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| Trimebutine SCHEMBL7428847 | 0.94 | OPRM1 (0.98) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| SCHEMBL16522145 | 0.88 | OPRM1 (0.88) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| SCHEMBL14317655 | 0.86 | OPRM1 (0.83) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| Trimebutine SCHEMBL2017641 | 0.86 | ALDH1A1 (0.74) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| Maleic Acid SCHEMBL9832430 | 0.85 | ALDH1A1 (0.74) | ALDH1A1MAPTKMT2AOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1083 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119591509-A | Synthesis method of trimebutine intermediate and trimebutine maleate | 五峰赤诚生物科技股份有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119564603-A | Trimebutine maleate resin compound slow-release suspension and preparation method thereof | 平光制药股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-119185222-A | Trimebutine maleate sublingual tablet and preparation method thereof | 但丁生物科技(山东)有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-118930443-A | Synthesis method of trimebutine intermediate and trimebutine maleate | 五峰赤诚生物科技股份有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20240368651-A1 | CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2024-11-07 | — | — | US | claimed |
| CN-221938756-U | Trimebutine maleate tablet packing box | 信合援生制药股份有限公司 | 2024-11-01 | — | — | CN | claimed |
| CN-116211847-B | Application of saururus chinensis ketone in preparation of medicine for preventing and/or treating irritable bowel syndrome | 四川省医学科学院·四川省人民医院 | 2024-09-13 | — | — | CN | claimed |
| CN-114858960-B | Glycosidic bond connection mode analysis database and construction method and application thereof | 梁军 | 2024-09-10 | — | — | CN | claimed |
| CN-118384299-A | Medical organism in-vivo endoscope positioning marking liquid and preparation and application thereof | 江苏德威兰医疗器械股份有限公司 | 2024-07-26 | — | — | CN | claimed |
| CN-115385806-B | Process for preparing trimebutine and trimebutine maleate | 山西双雁药业有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-1507861-A | Trimebutine maleate tablet and preparing method thereof | 海南普利制药有限公司 | 2004-06-30 | — | — | CN | claimed |
| CN-1504185-A | Pharmaceutical composition | 中外制药株式会社 | 2004-06-16 | — | — | CN | claimed |
| US-20030185886-A1 | Process for the preparation of rapidly disintegrating tablet | HANMI PHARM. CO., LTD. | 2003-10-02 | — | — | US | claimed |
| EP-1283703-A1 | RAPIDLY DISINTEGRATING TABLET AND PROCESS FOR THE MANUFACTURE THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2003-02-19 | — | — | EP | claimed |
| US-20020001617-A1 | Rapidly disintegrating tablet and process for the manufacture thereof | HANMI PHARM. CO., LTD. (KR) | 2002-01-03 | — | — | US | claimed |
| WO-2001089485-A1 | RAPIDLY DISINTEGRATING TABLET AND PROCESS FOR THE MANUFACTURE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2001-11-29 | — | — | WO | claimed |
| CN-1226162-A | Coated trimebutine maleate tablet | PARK DAVIS CO LTD (FR) | 1999-08-18 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |